Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer

Deng, Lili; Deng, Hong-Bin; Lu, Changlian; Guo, Yang; Wang, Di; Yan, Chunhua; Lv, Xing; Shao, Yi

doi:10.1007/s00432-014-1751-y

Cited by 8 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The relationship between EGFR mutation and peripheral structure invasion can provide a basis for comprehensive therapy. Indeed, postoperative patients with EGFR mutation show higher efficacy rates to targeted therapy and chemotherapy compared with wild-type patients [21]. Patients harboring EGFR mutation are prone to recurrence in the incision margin [22–24], and have a high metastasis rate [25]; however, they still show higher survival after recurrence [26–28].…”

Section: Discussionmentioning

confidence: 99%

“…Patients harboring EGFR mutation are prone to recurrence in the incision margin [22–24], and have a high metastasis rate [25]; however, they still show higher survival after recurrence [26–28]. For instance, the 5-year survival rate in patients with EGFR mutation was shown to be higher than that of cases without mutation [21], which may be related to drug sensitivity and comprehensive treatment. Therefore, clarifying the clinical characteristics of early lung adenocarcinoma patients with EGFR mutation aims to provide a basis for clinical treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma

Nie

Gao

et al. 2017

World J Surg Onc

View full text Add to dashboard Cite

BackgroundResectable lung adenocarcinoma is dominated by peripheral distribution, and surgical resection is the main treatment protocol. However, high recurrence rate remains after surgery. Lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation has strong invasion ability, but the effects of this mutation on local invasion in early lung adenocarcinoma have been rarely studied. This study aimed to assess the effects of EGFR mutation on local invasion in resectable lung adenocarcinoma.MethodsA retrospective analysis of 103 patients clinically diagnosed with peripheral lung adenocarcinoma was included. They underwent preoperative bronchoscopy, which indicated grades 2 or 3 bronchial involvement (lumen of the lobe or segment). The associations of EGFR mutation with pleural invasion, endobronchial metastasis, and lymph node metastasis were analyzed according to pathologies of pleural invasion and lymph node metastasis, as well as EGFR gene mutation detected by postoperative pathological specimens. Statistical analyses were performed by unpaired Chi-square test using the SPSS16.0 software.ResultsIn patients with EGFR mutation, pleural invasion, endobronchial metastasis, and lymph node metastasis rates were 62.5, 39.1, and 34.4%, respectively, indicating statistically significant differences (p = 0.003). Meanwhile, the pleural invasion rate in patients with wild-type EGFR was 43.6%, significantly reduced compared with patients with mutated EGFR (62.5%; p = 0.018). In addition, the endobronchial metastasis rate in patients with wild-type EGFR was 17.9%, significantly lower than in patients with EGFR mutation (39.1%; p = 0.005). However, lymph node metastasis rates were similar between EGFR mutated and wild-type patients (34.4 vs 25.6%, respectively, p > 0.05).ConclusionsEarly resectable lung adenocarcinoma patients with EGFR mutation showed a higher rate of local invasion compared with those harboring wild-type EGFR. This finding provides a basis for improved therapy.Trial registrationThis study was supported by Project of Medical and Health Science Technology in Shandong Province (2015WS0376)

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma

Nie

Gao

et al. 2017

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…Furthermore, it has been proven that the pathological immunohistochemistry and expression of biological markers between biopsy samples and surgical samples are well correlated (7 ,13–15 ). In the past 10 years, multi-gene detection analysis has been done using biopsy samples, which provide important gene phenotyping decision-making evidence for the use of treatment drugs such as molecular-targeted drugs (14–17). The success rate of PDTX modeling using surgical samples has been reported to be 25–40% (11,18,19).…”

Section: Discussionmentioning

confidence: 99%

Establishment of patient-derived tumor xenograft (PDTX) models using samples from CT-guided percutaneous biopsy

Zhuang

Zhu²,

Wang

et al. 2017

Braz J Med Biol Res

View full text Add to dashboard Cite

This study aimed to investigate the feasibility of the establishment of a human cancer xenograft model using samples from computed tomography (CT)-guided percutaneous biopsy. Fresh tumor tissues obtained from 10 cancer patients by CT-guided percutaneous biopsy were subcutaneously inoculated into NOD-Prkdcem26Il2rgem26Nju (NCG) mice to establish human patient-derived tumor xenograft (PDTX) models. The formation of first and second generation xenografts was observed, and tumor volume was recorded over time. Tumor tissue consistency between the PDTX model and primary tumors in patients was compared using H&E staining and immunohistochemistry. Pharmacodynamic tests of clinically used chemotherapeutic drugs were conducted on second generation xenografts, and their effects on tumor growth and body weight were observed. CT-guided percutaneous biopsy samples were successfully collected from 10 patients with advanced cancers. The PDTX model was established in mice using tumor samples obtained from 4 cancer patients, including one small cell carcinoma sample, two adenocarcinoma samples, and one squamous cell carcinoma sample. The success rate was 40%. The obtained PDTX model maintained a degree of differentiation, and morphological and structural characteristics were similar to primary tumors. The pharmacodynamic test of chemotherapeutic drugs in the PDTX model revealed a therapeutic effect on tumor growth, as expected. CT-guided percutaneous biopsy samples can be effectively used to establish a PDTX model, and test these chemotherapy regimens.

show abstract

“…In addition, poorly differentiated tumors may also be correlated with chemoresistance in NSCLC . A recent study revealed that the expression of excision repair cross‐complementing group 1 (ERCC1), which repairs platinum‐induced DNA damage in patients with poorly differentiated adenocarcinoma, was significantly higher than that found in patients with well‐moderately differentiated non‐adenocarcinomas . This finding suggests that high levels of ERCC1 expression in poorly differentiated tumors may be predictive of a poor response to platinum‐based chemotherapy in NSCLC.…”

Section: Discussionmentioning

confidence: 99%

Heterogeneous prognosis and adjuvant chemotherapy in pathological stage I non‐small cell lung cancer patients

et al. 2015

View full text Add to dashboard Cite

BackgroundEven after curative resection, the prognosis of pathological stage I non-small cell lung cancer (NSCLC) can be heterogeneous, and the use of adjuvant chemotherapy in these patients is controversial. We aimed to identify the prognostic factors and role of adjuvant chemotherapy in pathological stage I NSCLC.MethodsWe retrospectively analyzed the correlations between clinicopathological factors and survival in 179 patients with resected pathological stage I NSCLC.ResultsAfter a median follow-up of 93 months, overall and disease-free survival were not significantly different between pathological stage IA (n = 138) and IB (n = 41) patients. The prognosis of pathological stage I patients with poorly differentiated tumors was significantly worse than that of those with non-poorly differentiated tumors (P = 0.003). Multivariate analysis revealed that poor tumor differentiation was an independent factor for poor survival (hazard ratio = 6.889). A marginally significant survival benefit was observed in poorly differentiated pathological stage I patients who received adjuvant chemotherapy (P = 0.053).Pathological stage IA patients who received adjuvant chemotherapy had a worse prognosis than those who did not receive adjuvant chemotherapy (P < 0.001), whereas pathological stage IA patients with poorly differentiated tumors who received adjuvant chemotherapy had better survival than who did not receive adjuvant chemotherapy (P < 0.001).ConclusionsPoor differentiation is an independent prognostic factor in pathological stage I NSCLC after surgical resection. Adjuvant chemotherapy may be beneficial in poorly differentiated pathological stage IA NSCLC patients.

show abstract

Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer

Abstract: Mutations and expression of chemotherapy-related genes may provide a basis for the selection of suitable molecular markers for individual treatment in a population with stage IIIB and IV NSCLC.

Cited by 8 publications

References 39 publications

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma

Establishment of patient-derived tumor xenograft (PDTX) models using samples from CT-guided percutaneous biopsy

Heterogeneous prognosis and adjuvant chemotherapy in pathological stage I non‐small cell lung cancer patients

Contact Info

Product

Resources

About